| Message : | I've only just arrived http://www.iris-community-management.fr/duphaston-medscape-8680.pdf duphaston medscape
On Wednesday, Pfizer said tofacitinib met its primary effectiveness goal in a separate Phase III psoriasis study, called OPT Retreatment, which lasted 56 weeks and compared the 5 milligram and 10 milligram doses of tofacitinib to a placebo.
***---REPLIED TO MESSAGE BELOW---***
I've only just arrived http://www.iris-community-management.fr/duphaston-medscape-8680.pdf duphaston medscape
On Wednesday, Pfizer said tofacitinib met its primary effectiveness goal in a separate Phase III psoriasis study, called OPT Retreatment, which lasted 56 weeks and compared the 5 milligram and 10 milligram doses of tofacitinib to a placebo.
|